BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Migraine clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for migraine: 66 (28 sponsors; 16 newly posted in the last 180 days, 5 stopped in the last 180 days; 6 new-entrant sponsors). Momentum score 25, rank 12 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 1, Phase 2 5, Phase 3 29, Phase 4 5, N/A 26.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AbbVie ABBV | 13 | NA 5, P3 7, P2 1 | 1 | 3 |
| Pfizer PFE | 14 | NA 5, P4 2, P3 6, P1 1 | 4 | 2 |
| H. Lundbeck A/S | 3 | P3 3 | 0 | 1 |
| TriGemX Bio, Inc. new entrant | 3 | P3 3 | 3 | 1 |
| Ipsen | 3 | P2 1, P3 2 | 0 | 0 |
| Brise Pharmaceuticals Co., Ltd. new entrant | 2 | P3 2 | 2 | 0 |
| Eli Lilly and Company LLY | 2 | P3 2 | 0 | 0 |
| Merz Therapeutics GmbH | 2 | P3 2 | 0 | 2 |
| Amgen AMGN | 2 | NA 1, P3 1 | 0 | 0 |
| Dr George Medvedev | 1 | P3 1 | 0 | 0 |
| Salvia BioElectronics | 3 | NA 3 | 1 | 1 |
| Theranica | 2 | NA 1, P4 1 | 1 | 0 |
| Abilion Medical Systems AB | 1 | NA 1 | 0 | 0 |
| Alasht Pharmed | 1 | P4 1 | 0 | 0 |
| Aspeya, Inc. new entrant | 1 | P2 1 | 1 | 1 |
| Brightmind.AI | 1 | NA 1 | 0 | 0 |
| Cefaly Technology | 1 | NA 1 | 0 | 1 |
| Cerenovus, Part of DePuy Synthes Products, Inc. | 1 | NA 1 | 0 | 1 |
| Cortex Neurovascular new entrant | 1 | NA 1 | 1 | 0 |
| Danone Nutricia SpA Società Benefit | 1 | NA 1 | 0 | 0 |
| Evommune, Inc. EVMN new entrant | 1 | P2 1 | 1 | 0 |
| Hinge Health, Inc HNGE new entrant | 1 | NA 1 | 1 | 0 |
| Libbs Farmacêutica LTDA | 1 | NA 1 | 0 | 0 |
| Otsuka Pharmaceutical Co., Ltd. | 1 | NA 1 | 0 | 0 |
| Power Life Sciences Inc. | 1 | NA 1 | 0 | 0 |
New-entrant sponsors: TriGemX Bio, Inc., Brise Pharmaceuticals Co., Ltd., Aspeya, Inc., Cortex Neurovascular, Evommune, Inc., Hinge Health, Inc.
Recently stopped trials
- NCT07116499 TriGemX Bio, Inc. - terminated: Study stopped for futility based on an interim analysis of efficacy. A Study of K-645 in the Treatment of Multiple Migraine Attacks
- NCT07313800 Cortex Neurovascular - withdrawn: The study was not initiated. IRB review determined the study would require an investigational device exemption (IDE), and the sponsor electe EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization
- NCT04396236 Eli Lilly and Company - terminated: Study terminated due to strategic business decision A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
- NCT04396574 Eli Lilly and Company - terminated: Study terminated due to strategic business decision A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
- NCT04100135 W.L.Gore & Associates - terminated: Dissatisfactory enrollment rate with no safety concerns GORE® CARDIOFORM Septal Occluder Migraine Clinical Study
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-29 est. | P3 | Pfizer PFE | NCT06641466 A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | Menstrual Migraine | recruiting | 723 |
| 2027-02 est. | P2 | AbbVie ABBV | NCT06602479 A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine | Migraine | active not recruiting | 309 |
| 2027-02 est. | P3 | TriGemX Bio, Inc. | NCT07645924 A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | Migraine | recruiting | 1800 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09 est. | P2 | Sichuan Purity Pharmaceutical Technology Co., Ltd. | NCT07304518 Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults | Migraine | recruiting | 456 |
| 2026-06-29 | P3 | AbbVie ABBV | NCT06806293 Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | Menstrual Migraine (MM) | active not recruiting | 468 |
| 2026-06-01 | P3 | Ipsen | NCT06047457 A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults | Episodic Migraine | active not recruiting | 751 |
| 2026-05-28 | P3 | Ipsen | NCT06047444 A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults | Chronic Migraine | active not recruiting | 759 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "migraine"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.